CA2984154A1 - Peptide compositions and methods of use - Google Patents

Peptide compositions and methods of use

Info

Publication number
CA2984154A1
CA2984154A1 CA2984154A CA2984154A CA2984154A1 CA 2984154 A1 CA2984154 A1 CA 2984154A1 CA 2984154 A CA2984154 A CA 2984154A CA 2984154 A CA2984154 A CA 2984154A CA 2984154 A1 CA2984154 A1 CA 2984154A1
Authority
CA
Canada
Prior art keywords
retinal
composition
compound
disease
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2984154A
Other languages
English (en)
French (fr)
Inventor
Cagri G. Besirli
Alexander J. Bridges
John K. Freshley
William A. Hunke
Linda L. Johnson
Francis X. Smith
Ethan SYLVAIN
David N. Zacks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
ONL Therapeutics Inc
Original Assignee
University of Michigan System
ONL Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, ONL Therapeutics Inc filed Critical University of Michigan System
Publication of CA2984154A1 publication Critical patent/CA2984154A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2984154A 2015-05-01 2016-04-29 Peptide compositions and methods of use Pending CA2984154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
US62/155,711 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (1)

Publication Number Publication Date
CA2984154A1 true CA2984154A1 (en) 2016-11-10

Family

ID=57217771

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2984154A Pending CA2984154A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Country Status (21)

Country Link
US (5) US10508134B2 (enExample)
EP (3) EP3288379B1 (enExample)
JP (2) JP6884755B2 (enExample)
KR (2) KR102652804B1 (enExample)
CN (2) CN113651873B (enExample)
AU (1) AU2016258837B2 (enExample)
CA (1) CA2984154A1 (enExample)
CY (1) CY1124911T1 (enExample)
DK (1) DK3288379T3 (enExample)
EA (2) EA035293B1 (enExample)
ES (1) ES2906173T3 (enExample)
HR (1) HRP20220138T1 (enExample)
HU (1) HUE057883T2 (enExample)
LT (1) LT3288379T (enExample)
MX (1) MX387317B (enExample)
PL (1) PL3288379T3 (enExample)
PT (1) PT3288379T (enExample)
RS (1) RS62866B1 (enExample)
SI (1) SI3288379T1 (enExample)
SM (1) SMT202200069T1 (enExample)
WO (1) WO2016178993A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288379B1 (en) 2015-05-01 2021-11-03 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2019183246A1 (en) * 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
JP2023507603A (ja) * 2019-12-18 2023-02-24 セラ セラピューティクス エルエルシー 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系
EP4355349A4 (en) * 2021-06-15 2025-04-16 ONL Therapeutics, Inc. Methods and compositions for treating eye diseases and disorders
JP2024525805A (ja) * 2021-07-13 2024-07-12 オーエヌエル セラピューティクス，インク． 眼の疾患および障害における視機能を改善するための方法および組成物
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
EP4565596A1 (en) * 2022-08-05 2025-06-11 ONL Therapeutics, Inc. Peptide compositions and methods of use
WO2024031022A2 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2024220669A1 (en) * 2023-04-19 2024-10-24 Onl Therapeutics, Inc. Methods and compositions for treating rnfl thinning

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
JP2008500816A (ja) 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
EP1737483A2 (en) 2004-04-23 2007-01-03 University of Pittsburgh of the Commonwealth System of Higher Education Cell death modulation via antagonists of fasl and fas activation
DK1885336T3 (da) 2005-05-10 2009-05-25 Alcon Inc Suspensionsformuleringer, der omfatter et aktivt princip, et overfladeaktivt poloxamer- eller meroxapolmiddel og en glycol, samt deres anvendelse til fremstilling af et medikament til behandling af öjenlidelser
US20070225217A1 (en) * 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
AU2006320327A1 (en) * 2005-12-01 2007-06-07 Duke University Compounds and methods for inhibiting apoptosis
EP2222696A1 (en) * 2007-12-21 2010-09-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
JP5643237B2 (ja) 2009-03-03 2014-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 光受容細胞のアポトーシスを抑制する方法
KR20120022721A (ko) * 2009-03-30 2012-03-12 산텐 세이야꾸 가부시키가이샤 ＪＮＫ(ｃ-Ｊｕｎ 아미노 말단 키나제) 저해 펩티드를 이용한 망막 질환의 예방 또는 치료제, 망막 질환의 예방 또는 치료 방법, 및 이 펩티드의 용도
CN102574822A (zh) * 2009-08-04 2012-07-11 阿米拉制药公司 作为溶血磷脂酸受体拮抗剂的化合物
WO2012115980A1 (en) 2011-02-22 2012-08-30 California Institute Of Technology Delivery of proteins using adeno-associated virus (aav) vectors
TW201542231A (zh) * 2011-06-06 2015-11-16 Kineta One Llc 以ｓｈｋ為主之醫藥組合物及其製備方法及用途
US9428550B2 (en) 2012-01-18 2016-08-30 Governing Council Of The University Of Toronto Peptides and methods and uses thereof for preventing retinal disorders
KR101514238B1 (ko) * 2012-06-21 2015-04-28 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드의 신규 용도
WO2014071183A1 (en) * 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
EP3254106A4 (en) 2015-02-05 2018-10-03 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
EP3288379B1 (en) 2015-05-01 2021-11-03 Onl Therapeutics, Inc. Peptide compositions and methods of use
KR20190096329A (ko) 2016-07-05 2019-08-19 유니버시티 오브 매사추세츠 녹내장에서 신경보호 요법으로서 sfasl의 aav2-매개된 유전자 전달
WO2018237148A1 (en) 2017-06-21 2018-12-27 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
WO2019183246A1 (en) 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
CN112566622A (zh) 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统

Also Published As

Publication number Publication date
BR112017023479A2 (pt) 2018-07-24
PL3288379T3 (pl) 2022-03-07
HK1251979A1 (zh) 2019-05-10
JP6884755B2 (ja) 2021-06-09
US11597749B2 (en) 2023-03-07
ES2906173T3 (es) 2022-04-13
CY1124911T1 (el) 2023-01-05
CN107708416B (zh) 2021-06-29
EP4623925A2 (en) 2025-10-01
EA201792399A1 (ru) 2018-05-31
CN113651873A (zh) 2021-11-16
JP2018514590A (ja) 2018-06-07
KR102652804B1 (ko) 2024-04-01
AU2016258837A1 (en) 2017-11-09
RS62866B1 (sr) 2022-02-28
EA202090184A3 (ru) 2020-07-31
US10508134B2 (en) 2019-12-17
EP3288379B1 (en) 2021-11-03
HRP20220138T1 (hr) 2022-05-27
US20200123201A1 (en) 2020-04-23
EA202090184A2 (ru) 2020-05-31
EP3288379A1 (en) 2018-03-07
HUE057883T2 (hu) 2022-06-28
EP3997981A1 (en) 2022-05-18
JP2021120400A (ja) 2021-08-19
AU2016258837B2 (en) 2020-12-03
WO2016178993A1 (en) 2016-11-10
US12258425B2 (en) 2025-03-25
EA035293B1 (ru) 2020-05-26
CN113651873B (zh) 2025-09-02
SMT202200069T1 (it) 2022-03-21
US10829518B2 (en) 2020-11-10
US20210094985A1 (en) 2021-04-01
MX387317B (es) 2025-03-18
US20250346631A1 (en) 2025-11-13
KR20240046280A (ko) 2024-04-08
KR20170140383A (ko) 2017-12-20
CN107708416A (zh) 2018-02-16
DK3288379T3 (da) 2022-02-07
EP3288379A4 (en) 2018-10-24
SI3288379T1 (sl) 2022-06-30
LT3288379T (lt) 2022-02-25
MX2017014075A (es) 2018-07-06
US20180291062A1 (en) 2018-10-11
PT3288379T (pt) 2022-02-08
US20230287052A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
US12258425B2 (en) Peptide compositions and methods of use
ES2562912T5 (es) Procedimiento de estabilización de un anticuerpo y preparación de anticuerpo de tipo disolución estabilizada
CN111163757B (zh) 眼用制剂
CA3054290A1 (en) Stable peptide compositions
AU2019407063B2 (en) Protein solution formulation containing high concentration of an anti-VEGF antibody
US20190201500A1 (en) Compositions and methods of fas inhibition
US20250099533A1 (en) Adiponectin peptidomimetics formulations
US20160376239A1 (en) N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use
HK1251979B (en) Peptide compositions and methods of use
BR112017023479B1 (pt) Composto, composição e uso de um composto ou composição
EA047252B1 (ru) Стабильные составы рекомбинантных белков
CN115298206A (zh) 眼科药物组合物及其用途
US20170112821A1 (en) Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210426

EEER Examination request

Effective date: 20210426

EEER Examination request

Effective date: 20210426

EEER Examination request

Effective date: 20210426

EEER Examination request

Effective date: 20210426

EEER Examination request

Effective date: 20210426

EEER Examination request

Effective date: 20210426

EEER Examination request

Effective date: 20210426